| Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer HI Scher, D Lu, NA Schreiber, J Louw, RP Graf, HA Vargas, A Johnson, ... JAMA oncology 2 (11), 1441-1449, 2016 | 642 | 2016 |
| Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer HI Scher, RP Graf, NA Schreiber, A Jayaram, E Winquist, B McLaughlin, ... JAMA oncology 4 (9), 1179-1186, 2018 | 220 | 2018 |
| Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a … KA Autio, R Dreicer, J Anderson, JA Garcia, A Alva, LL Hart, MI Milowsky, ... JAMA oncology 4 (10), 1344-1351, 2018 | 198 | 2018 |
| Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer HI Scher, RP Graf, NA Schreiber, B McLaughlin, D Lu, J Louw, DC Danila, ... European urology 71 (6), 874-882, 2017 | 174 | 2017 |
| Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer K Boudadi, DL Suzman, V Anagnostou, W Fu, B Luber, H Wang, ... Oncotarget 9 (47), 28561, 2018 | 144 | 2018 |
| The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer H Beltran, A Jendrisak, M Landers, JM Mosquera, M Kossai, J Louw, ... Clinical Cancer Research 22 (6), 1510-1519, 2016 | 142 | 2016 |
| Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms H Tukachinsky, RW Madison, JH Chung, OV Gjoerup, EA Severson, ... Clinical Cancer Research 27 (11), 3094-3105, 2021 | 128 | 2021 |
| Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer HI Scher, RP Graf, NA Schreiber, B McLaughlin, A Jendrisak, Y Wang, ... Cancer research 77 (20), 5687-5698, 2017 | 125 | 2017 |
| Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients A Anantharaman, T Friedlander, D Lu, R Krupa, G Premasekharan, ... BMC cancer 16, 1-11, 2016 | 121 | 2016 |
| Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival DJ Boffa, RP Graf, MC Salazar, J Hoag, D Lu, R Krupa, J Louw, L Dugan, ... Cancer Epidemiology, Biomarkers & Prevention 26 (7), 1139-1145, 2017 | 76 | 2017 |
| Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer AS McDaniel, R Ferraldeschi, R Krupa, M Landers, R Graf, J Louw, ... BJU international 120 (5B), E30-E44, 2017 | 68 | 2017 |
| Clinical utility of the nuclear-localized AR-V7 biomarker in circulating tumor cells in improving physician treatment choice in castration-resistant prostate cancer RP Graf, M Hullings, ES Barnett, E Carbone, R Dittamore, HI Scher European urology 77 (2), 170-177, 2020 | 65 | 2020 |
| Caspase-8 as a regulator of tumor cell motility RP Graf, N Keller, S Barbero, D Stupack Current molecular medicine 14 (2), 246-254, 2014 | 64 | 2014 |
| Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer PD Malihi, RP Graf, A Rodriguez, N Ramesh, J Lee, R Sutton, R Jiles, ... Clinical Cancer Research 26 (15), 4143-4153, 2020 | 58 | 2020 |
| Chromosomal instability estimation based on next generation sequencing and single cell genome wide copy number variation analysis SB Greene, AE Dago, LJ Leitz, Y Wang, J Lee, SL Werner, S Gendreau, ... PLoS One 11 (11), e0165089, 2016 | 47 | 2016 |
| Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer RP Graf, V Fisher, J Weberpals, O Gjoerup, MB Tierno, RSP Huang, ... JAMA network Open 5 (3), e225394-e225394, 2022 | 41 | 2022 |
| The death effector domains of caspase-8 induce terminal differentiation A Mielgo, VA Torres, MC Schmid, R Graf, SG Zeitlin, P Lee, DJ Shields, ... PLoS One 4 (11), e7879, 2009 | 30 | 2009 |
| Circulating tumor cells as a predictor of treatment response in clinically localized prostate cancer SS Salami, U Singhal, DE Spratt, GS Palapattu, BK Hollenbeck, ... JCO precision oncology 3, 1-9, 2019 | 29 | 2019 |
| SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer U Swami, RP Graf, RH Nussenzveig, V Fisher, H Tukachinsky, ... Clinical Cancer Research 28 (22), 4917-4925, 2022 | 25 | 2022 |
| Androgen receptor expression on circulating tumor cells in metastatic breast cancer T Fujii, JM Reuben, L Huo, JR Espinosa Fernandez, Y Gong, R Krupa, ... PLoS One 12 (9), e0185231, 2017 | 23 | 2017 |
